These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35233616)

  • 21. An initiative to improve pneumococcal immunization counseling in children with nephrotic syndrome.
    Sandokji I; Anderson LS; Warejko JK; Emerson BL; Greenberg JH
    Pediatr Nephrol; 2022 Jun; 37(6):1333-1338. PubMed ID: 34734331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups.
    Liu Y; Xu Y; Wang J; Che X; Gu W; Du J; Zhang X; Zhang X; Jiang W; Chen J; An Z
    Hum Vaccin Immunother; 2021 Jan; 17(1):157-161. PubMed ID: 32530728
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.
    Juergens C; de Villiers PJ; Moodley K; Jayawardene D; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Hum Vaccin Immunother; 2014; 10(5):1343-53. PubMed ID: 24576885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementing a Nurse-Driven Protocol for Pneumococcal Vaccination in an Academic Rheumatology Clinic.
    Joerns EK; Pokala N; Bermas B; Reisch J; Wang DC; Arasaratnam R; Bajaj P
    J Rheumatol; 2023 Mar; 50(3):413-419. PubMed ID: 36319017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Previsit Planning Improves Pneumococcal Vaccination Rates in Childhood-Onset SLE.
    Sivaraman V; Wise KA; Cotton W; Barbar-Smiley F; AlAhmed O; MacDonald D; Lemle S; Yildirim-Toruner C; Ardoin SP; Ardura MI
    Pediatrics; 2020 Jan; 145(1):. PubMed ID: 31879277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong.
    Shami JJP; Pathadka S; Chan EW; Hui J; Sato R; Patil S; Li X
    Hum Vaccin Immunother; 2020 Aug; 16(8):1937-1944. PubMed ID: 31977268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Oct; 61(40):816-9. PubMed ID: 23051612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of pneumococcal vaccines for adults in the United States.
    Chen J; O'Brien MA; Yang HK; Grabenstein JD; Dasbach EJ
    Adv Ther; 2014 Apr; 31(4):392-409. PubMed ID: 24718851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving influenza and pneumococcal vaccination uptake among incident peritoneal dialysis patients: a quality improvement initiative.
    Tan HZ; Phang CC; Wu SY; Sim MH; Law MM; Foo MWY; Htay H
    Int Urol Nephrol; 2021 Oct; 53(10):2167-2175. PubMed ID: 33675479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009.
    Lu PJ; Nuorti JP
    Am J Epidemiol; 2012 Apr; 175(8):827-37. PubMed ID: 22403807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
    Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
    Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease.
    Han J; Kemiki O; Hsu LL; Rivers AE
    Pharmacotherapy; 2015 Jul; 35(7):696-700. PubMed ID: 26095207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of pneumococcal vaccination rates after vaccine protocol changes and nurse education in a tertiary care teaching hospital.
    Smith JG; Metzger NL
    J Manag Care Pharm; 2011 Nov; 17(9):701-8. PubMed ID: 22050395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of pneumococcal and influenza vaccination coverage in rheumatology patients receiving biological therapy in a regional referral hospital.
    Fernández-Prada M; Brandy-García AM; Rodríguez-Fonseca OD; Huerta-González I; Fernández-Noval F; Martínez-Ortega C
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 1):97-102. PubMed ID: 29752214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
    Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
    Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between family physician's direct advice and pneumococcal vaccination intention and behavior among the elderly in Japan: a cross-sectional study.
    Higuchi M; Narumoto K; Goto T; Inoue M
    BMC Fam Pract; 2018 Sep; 19(1):153. PubMed ID: 30185157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.